Cryoport Future Growth
Future criteria checks 1/6
Cryoport is forecast to grow earnings and revenue by 32% and 9.8% per annum respectively. EPS is expected to grow by 36% per annum. Return on equity is forecast to be -13.6% in 3 years.
Key information
32.0%
Earnings growth rate
36.0%
EPS growth rate
Life Sciences earnings growth | 21.7% |
Revenue growth rate | 9.8% |
Future return on equity | -13.6% |
Analyst coverage | Good |
Last updated | 08 May 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 296 | -61 | 15 | N/A | 5 |
12/31/2025 | 266 | -55 | -9 | N/A | 8 |
12/31/2024 | 243 | -69 | -39 | N/A | 9 |
3/31/2024 | 225 | -121 | N/A | N/A | N/A |
12/31/2023 | 233 | -108 | -46 | -1 | N/A |
9/30/2023 | 236 | -55 | -41 | 0 | N/A |
6/30/2023 | 241 | -47 | -32 | 3 | N/A |
3/31/2023 | 248 | -38 | -29 | 0 | N/A |
12/31/2022 | 237 | -45 | -26 | -2 | N/A |
9/30/2022 | 233 | -296 | -27 | -3 | N/A |
6/30/2022 | 230 | -297 | -23 | 5 | N/A |
3/31/2022 | 222 | -293 | -12 | 15 | N/A |
12/31/2021 | 223 | -284 | -17 | 8 | N/A |
9/30/2021 | 215 | -76 | -25 | -4 | N/A |
6/30/2021 | 169 | -78 | -32 | -18 | N/A |
3/31/2021 | 122 | -77 | -34 | -22 | N/A |
12/31/2020 | 79 | -75 | -25 | -15 | N/A |
9/30/2020 | 40 | -22 | -11 | -4 | N/A |
6/30/2020 | 38 | -23 | -6 | 0 | N/A |
3/31/2020 | 37 | -20 | -5 | 0 | N/A |
12/31/2019 | 34 | -18 | -7 | -1 | N/A |
9/30/2019 | 30 | -20 | -8 | -2 | N/A |
6/30/2019 | 26 | -9 | -7 | -2 | N/A |
3/31/2019 | 22 | -9 | -6 | -2 | N/A |
12/31/2018 | 20 | -10 | -6 | -3 | N/A |
9/30/2018 | 17 | -10 | -7 | -4 | N/A |
6/30/2018 | 15 | -9 | -6 | -5 | N/A |
3/31/2018 | 13 | -9 | -5 | -4 | N/A |
12/31/2017 | 12 | -8 | N/A | -4 | N/A |
9/30/2017 | 11 | -10 | N/A | -3 | N/A |
6/30/2017 | 10 | -10 | N/A | -4 | N/A |
3/31/2017 | 9 | -12 | N/A | -5 | N/A |
12/31/2016 | 8 | -13 | N/A | -6 | N/A |
9/30/2016 | 7 | -12 | N/A | -6 | N/A |
6/30/2016 | 6 | -12 | N/A | -6 | N/A |
3/31/2016 | 6 | -15 | N/A | -6 | N/A |
12/31/2015 | 6 | -16 | N/A | -6 | N/A |
9/30/2015 | 5 | -15 | N/A | -5 | N/A |
6/30/2015 | 4 | -16 | N/A | -5 | N/A |
3/31/2015 | 4 | -12 | N/A | -4 | N/A |
12/31/2014 | 4 | -10 | N/A | -4 | N/A |
9/30/2014 | 3 | -10 | N/A | -4 | N/A |
6/30/2014 | 3 | -21 | N/A | -4 | N/A |
3/31/2014 | 3 | -20 | N/A | -4 | N/A |
12/31/2013 | 2 | -20 | N/A | -4 | N/A |
9/30/2013 | 2 | -20 | N/A | -4 | N/A |
6/30/2013 | 1 | -6 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CKX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CKX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CKX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CKX's revenue (9.8% per year) is forecast to grow faster than the German market (5.3% per year).
High Growth Revenue: CKX's revenue (9.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CKX is forecast to be unprofitable in 3 years.